Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension...
Date First Received: August 31, 2005
Last Updated: May 10, 2007
Verified by: St George's, University of London, May 2007
Clinical Trial Phase: N/A | Start Date: April 2004
Overall Status: Recruiting
Estimated Enrollment: 11
Brief Summary
Official Title: “The Renin-Angiotensin System in Essential Hypertension”
Condition Keyword(s):
Intervention(s):
Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.
Study Type: Interventional
Study Design: Other, Randomized, Open Label, Active Control, Crossover Assignment
Intervention(s) in this Clinical Trial
- Drug: Enalapril 20 mg bd
- Drug: Candesartan 8 mg bd
Outcome Measures for this Clinical Trial
Primary Measures
- Change in BP
- Change in PRA and aldosterone
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Essential Hypertension
- SBP 140-159 mmHg
- DBP 90-99 mmHg
Exclusion Criteria:
- Intolerance of or allergy to ACE Inhibitors or ARBS
- Pregnant or Breastfeeding
- Pre-menopausal women
- Uncontrolled cardiac or renal failure
- Diabetes mellitus
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 70 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: St George's, University of London
Overall Clinical Trial Officials and Contacts
Timothy WR Doulton, BSc MRCP Principal Investigator SGUL
Overall Contact: Timothy WR Doulton, BSc MRCP +44 208 725 3176 tdoulton@sgul.ac.uk
Additional Information
Information obtained from ClinicalTrials.gov on August 28, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00141583
Study ID Number: LREC 01.87.10
ClinicalTrials.gov Identifier: NCT00141583
Health Authority: United Kingdom: Research Ethics Committee
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
